Biotech IPOs: Class of 2014 still rolling as investors line up to cash in

Damian Garde

The most likely indicator of whether 's Wall Street hot streak can last is whether are getting good returns on all these drug developer . And so far, the beneficiaries of 's boomlet are coming through.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS